Generating Evidence for Clinical Benefit of PET/CT in Diagnosing Cancer Patients

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

For diagnostic methods such as PET/CT, not only diagnostic accuracy but also clinical benefit must be demonstrated. However, there is a lack of consensus about how to approach this task. Here we consider 6 clinical scenarios to review some basic approaches to demonstrating the clinical benefit of PET/CT in cancer patients: replacement of an invasive procedure, improved accuracy of initial diagnosis, improved accuracy of staging for curative versus palliative treatment, improved accuracy of staging for radiation versus chemotherapy, response evaluation, and acceleration of clinical decisions. We also develop some guidelines for the evaluation of clinical benefit. First, it should be clarified whether there is a direct benefit of the use of PET/CT or an indirect benefit because of improved diagnostic accuracy. If there is an indirect benefit, then decision modeling should be used initially to assess the benefit expected from the use of PET/CT. Only if decision modeling does not allow definitive conclusions should randomized controlled trials be planned.
OriginalsprogEngelsk
TidsskriftJournal of Nuclear Medicine
Vol/bind52
Udgave nummerSuppl 2
Sider (fra-til)77S-85S
Antal sider9
ISSN0161-5505
DOI
StatusUdgivet - 2011

Fingeraftryk

Decision Support Techniques
Palliative Care
Neoplasms
Randomized Controlled Trials
Guidelines

Citer dette

@article{b4183c8cb21b47fbae3f21ac33f28c2d,
title = "Generating Evidence for Clinical Benefit of PET/CT in Diagnosing Cancer Patients",
abstract = "For diagnostic methods such as PET/CT, not only diagnostic accuracy but also clinical benefit must be demonstrated. However, there is a lack of consensus about how to approach this task. Here we consider 6 clinical scenarios to review some basic approaches to demonstrating the clinical benefit of PET/CT in cancer patients: replacement of an invasive procedure, improved accuracy of initial diagnosis, improved accuracy of staging for curative versus palliative treatment, improved accuracy of staging for radiation versus chemotherapy, response evaluation, and acceleration of clinical decisions. We also develop some guidelines for the evaluation of clinical benefit. First, it should be clarified whether there is a direct benefit of the use of PET/CT or an indirect benefit because of improved diagnostic accuracy. If there is an indirect benefit, then decision modeling should be used initially to assess the benefit expected from the use of PET/CT. Only if decision modeling does not allow definitive conclusions should randomized controlled trials be planned.",
author = "Werner Vach and H{\o}ilund-Carlsen, {Poul Flemming} and Oke Gerke and Weber, {Wolfgang A}",
year = "2011",
doi = "10.2967/jnumed.110.085704",
language = "English",
volume = "52",
pages = "77S--85S",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine",
number = "Suppl 2",

}

Generating Evidence for Clinical Benefit of PET/CT in Diagnosing Cancer Patients. / Vach, Werner; Høilund-Carlsen, Poul Flemming; Gerke, Oke; Weber, Wolfgang A.

I: Journal of Nuclear Medicine, Bind 52, Nr. Suppl 2, 2011, s. 77S-85S.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Generating Evidence for Clinical Benefit of PET/CT in Diagnosing Cancer Patients

AU - Vach, Werner

AU - Høilund-Carlsen, Poul Flemming

AU - Gerke, Oke

AU - Weber, Wolfgang A

PY - 2011

Y1 - 2011

N2 - For diagnostic methods such as PET/CT, not only diagnostic accuracy but also clinical benefit must be demonstrated. However, there is a lack of consensus about how to approach this task. Here we consider 6 clinical scenarios to review some basic approaches to demonstrating the clinical benefit of PET/CT in cancer patients: replacement of an invasive procedure, improved accuracy of initial diagnosis, improved accuracy of staging for curative versus palliative treatment, improved accuracy of staging for radiation versus chemotherapy, response evaluation, and acceleration of clinical decisions. We also develop some guidelines for the evaluation of clinical benefit. First, it should be clarified whether there is a direct benefit of the use of PET/CT or an indirect benefit because of improved diagnostic accuracy. If there is an indirect benefit, then decision modeling should be used initially to assess the benefit expected from the use of PET/CT. Only if decision modeling does not allow definitive conclusions should randomized controlled trials be planned.

AB - For diagnostic methods such as PET/CT, not only diagnostic accuracy but also clinical benefit must be demonstrated. However, there is a lack of consensus about how to approach this task. Here we consider 6 clinical scenarios to review some basic approaches to demonstrating the clinical benefit of PET/CT in cancer patients: replacement of an invasive procedure, improved accuracy of initial diagnosis, improved accuracy of staging for curative versus palliative treatment, improved accuracy of staging for radiation versus chemotherapy, response evaluation, and acceleration of clinical decisions. We also develop some guidelines for the evaluation of clinical benefit. First, it should be clarified whether there is a direct benefit of the use of PET/CT or an indirect benefit because of improved diagnostic accuracy. If there is an indirect benefit, then decision modeling should be used initially to assess the benefit expected from the use of PET/CT. Only if decision modeling does not allow definitive conclusions should randomized controlled trials be planned.

U2 - 10.2967/jnumed.110.085704

DO - 10.2967/jnumed.110.085704

M3 - Journal article

C2 - 22144559

VL - 52

SP - 77S-85S

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - Suppl 2

ER -